Core Insights - Danaher Corporation (DHR) is set to release its third-quarter 2025 results on October 21, before market open [1][11] Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues is $6.00 billion, reflecting a 3.4% increase from the same quarter last year [2] - The consensus estimate for earnings is $1.72 per share, indicating a 0.6% increase from the year-ago quarter [2] - Danaher has surpassed the Zacks Consensus Estimate in three of the last four quarters, with an average beat of 8.5% [2] Segment Performance - The Life Sciences segment is expected to face challenges due to lower demand in protein consumables, flow cytometry, and lab automation solutions, with revenues projected to increase by 2.5% to $1.83 billion [4] - The Biotechnology segment is anticipated to benefit from strong demand for bioprocessing, with revenues expected to rise 8.9% to $1.80 billion [7] - The Diagnostics segment is likely to see modest growth, with revenues projected to increase by 0.4% to $2.37 billion, driven by the Beckman Coulter Diagnostics unit [8] Cost and Expenses - Danaher is experiencing rising costs, with cost of sales expected to increase by 5.8% year over year to $2.54 billion and SG&A expenses anticipated to rise by 7.7% to $1.53 billion [5] International Exposure - The company has significant exposure to international markets, which may negatively impact profitability due to foreign currency headwinds [6] Recent Acquisitions - Danaher acquired Abcam plc in December 2023, enhancing its Life Sciences segment with a strong product portfolio and innovation capabilities [9] Earnings Prediction - The current Earnings ESP for Danaher is -0.39%, indicating a lower likelihood of an earnings beat this quarter [10]

Core Insights - Danaher Corporation (DHR) is set to release its second-quarter 2025 results on July 22, before market open [1] Revenue Estimates - The Zacks Consensus Estimate for revenues is $5.84 billion, reflecting a 1.6% increase from the same quarter last year [2] - The consensus estimate for earnings is $1.64 per share, indicating a 4.7% decrease from the year-ago quarter [2] Segment Performance - The Life Sciences segment is expected to see a revenue decline of 3.4% to $1.71 billion due to weak demand in protein consumables, flow cytometry, and lab automation solutions [3] - The Biotechnology segment is projected to grow by 7% to $1.83 billion, driven by increased demand for bioprocessing consumables from large pharmaceutical customers [5] - The Diagnostics segment is anticipated to increase by 1.1% to $2.29 billion, supported by solid momentum in pathology and acute care diagnostics [6] Cost and Expenses - SG&A expenses are expected to rise by 5.8% to $1.55 billion, which may negatively impact the bottom line [4] - Foreign currency headwinds are likely to affect profitability due to significant international operations [4] Recent Developments - Danaher acquired Abcam plc in December 2023, enhancing its Life Sciences segment with a strong product portfolio and innovation capabilities [7] Earnings Prediction - The Earnings ESP for DHR is 0.00%, indicating no clear prediction for an earnings beat this quarter [9] - The company currently holds a Zacks Rank of 4 (Sell) [11]

Core Business Performance - Danaher Corporation has seen strong performance in its bioprocessing business, with orders increasing for the seventh consecutive quarter, and anticipates core revenues to rise in high-single-digits year-over-year for 2025 [1] - The Biotechnology segment is also performing well, with core revenues increasing by 7% year-over-year in the first quarter, and similar growth is expected for 2025 [2] Acquisitions and Growth Strategy - The company acquired Abcam plc for approximately $5.7 billion in December 2023, enhancing its Life Sciences segment and contributing to a 0.5% increase in total revenues in the first quarter [3] Shareholder Returns - Danaher is committed to returning value to shareholders, having paid dividends of $194 million in the first quarter of 2025, compared to $768 million in the same quarter of 2024, and increased its dividend by 18.5% to 32 cents per share in February 2025 [4] Segment Challenges - The Life Sciences segment faced a 4% decline in core revenues year-over-year due to lower demand in academic and government markets, as well as a sales decline in the filtration business [5] - The Diagnostics segment also struggled, with core revenues declining by 1.5% year-over-year due to sluggish demand for respiratory disease tests [8] Financial Position - Danaher reported long-term debt of $16 billion, a 3% increase sequentially, with current liabilities at $6.6 billion, exceeding cash equivalents of $2 billion, and high interest expenses of $72 million in the first quarter [9][10]